Szívelégtelenség: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• SGLT2 29
• GLP-1 6
• TTR 10
• AMPK 0
• NLRP3 0
• NRF2 0
• PI3K 0
• PPAR 0
• AKT 0
• mTOR 0
• HER2 2
• STAT3 0
• TP53 0
• MAPK 0
• SIRT1 0
• STING 0
• EGFR 0
• GIP 4
• HIF-1 0
• PCSK9 0
• DPP-4 0
• VEGF 0
• HMGB1 0
• IL-6 0
• CTNNB1 0
• TNF 0
• YAP 0
• PINK1 0
• ERK 0
• GPX4 0
• JAK 0
• TLR4 0
• IL-1 0
• JNK 0
• MEK 1
• HSP90 0
• DMD 0
• IL-17 0
• MMP-9 0
• PD-1 0
• CD40 0
• COX-2 0
• HDAC 0
• PD-L1 0
• TFEB 0
• ABL1 0
• APOE 0
• AR 0
• BCL-2 0
• FTO 0
• METTL3 0
• MYC 0
• PTEN 0
• ACE2 0
• BDNF 0
• BRAF 0
• BRD4 0
• BTK 0
• CDK4/6 0
• FAK 0

30+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Olaszország· EU contribution 193 643 EUR· until 2029. aug.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Bioinspired Modulation of Cardiac Troponin I Splicing to Treat Diastolic Dysfunction (TROPOSplice)

  Centro Nacional de Investigaciones Cardiovasculares Carlos Iii (F.s.p.)· Madrid, Spanyolország· EU contribution 1 499 625 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  From n=1 to many: Scaling-up gene editing for future heart therapies (ONE2MANY)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Németország· EU contribution 1 499 468 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Svájc· EU contribution 292 119 EUR· until 2028. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-CSA

  RAPid TranslatiOnal Research - Heart Failure (RAPTOR-HF)

  Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu· Wroclaw, Lengyelország· EU contribution 15 000 000 EUR· until 2032. dec.· 3 countries

5 of 84 running projects, newest first. Listed amounts together: 318,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia

  NCT06338839· AstraZeneca· Frissítve: 2025. szept. 18.

  “The study was suspended after interim analysis to confirm reasonability of further investigation of the population”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Novo Nordisk A/S· Forrás

• A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

  NCT06260709· Novo Nordisk A/S· Forrás

• Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· AstraZeneca· Forrás

• Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

  NCT06712030· Puerta de Hierro University Hospital· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 17
• Organoids 5
• Mendelian Randomization Analysis 79
• CRISPR-Cas Systems 7
• Gene Expression Profiling 71
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 10
• Proteomics 108
• Metabolomics 64
• Mass Spectrometry 5
• Flow Cytometry 10
• Immunohistochemistry 13
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 37
• Magnetic Resonance Imaging 155
• Machine Learning 198
• Deep Learning 42
• Cohort Studies 501
• Genome-Wide Association Study 74

• TOP3A pathogenic variants presenting as dilated cardiomyopathy and heart failure in three pediatric cases.

  BMC Pediatr, 2026. júl.

• Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants.

  Nat Med, 2026. jún.

• Infantile dilated cardiomyopathy caused by RPL3L gene mutation: A case report.

  J Int Med Res, 2026. máj.

• Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early-Onset Amyloid Cardiomyopathy.

  J Am Heart Assoc, 2026. máj.

• Fatal Infantile Cardiomyopathy Associated with a Homozygous MYL2 c.413T>A (p.Met138Lys) Variant: A Case Expanding the Recessive MYL2 Phenotypic Spectrum.

  Genes (Basel), 2026. ápr.

• From gene to heart: the impact of a novel SGCD variant in familial dilated cardiomyopathy.

  BMC Med Genomics, 2026. márc.

• Exome sequencing identifies potential variants linked to cardiovascular disease in Caldas, Colombia: insights from the ORIGEN COLOMBIAN genome project.

  Hum Mol Genet, 2026. febr.

• Clonal Hematopoiesis and Incident Heart Failure.

  JAMA Cardiol, 2026. febr.

• Impact of Rapid Exome Sequencing on Pediatric Patients With Cardiomyopathy and Acute Heart Failure.

  Am J Med Genet A, 2026. jan.

• Genetic mutations, pathology, and single-nucleus transcriptomic landscape in LVHT patients reveal differential progression to heart transplantation.

  Cardiovasc Pathol, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.